Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

75
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
75
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

195
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
195
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

5.1K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
5.1K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

88
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
88
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

270
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
270
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

34
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
34

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Detection of Ultrahigh Energy Emission from Gamma-Ray Binary LS I +61° 303.

Physical review letters·2026
Same author

Evidence of Cosmic-Ray Acceleration up to Sub-PeV Energies in the Supernova Remnant IC 443.

Physical review letters·2026
Same author

Precise Measurement of the Cosmic Ray Helium Spectrum above 0.1 PeV.

Physical review letters·2026
Same author

Rapid chemical characterization of finger millet using UHPLC-Q-Exactive orbitrap MS coupled with based via Feature-Based molecular networking and PRM.

Scientific reports·2026
Same author

[Association between serum vitamin A and E levels and asthma risk in children aged 1-14 years in some areas of Hunan Province].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2025
Same author

All-Sky Search for Individual Primordial Black Hole Bursts with LHAASO.

Physical review letters·2025

Related Experiment Video

Updated: Oct 20, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.8K

Cefoperazone/sulbactam-induced hemolytic anemia.

X M Sun1, L H Liu1, Q Wu2

  • 1Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

Journal of Postgraduate Medicine
|September 16, 2021
PubMed
Summary
This summary is machine-generated.

Drug-induced hemolytic anemia (DIHA) is a rare complication. Cefoperazone/sulbactam can cause DIHA, necessitating careful patient monitoring for early detection and prompt treatment.

Keywords:
Adverse reactionscefoperazonedrug-related side effectshemolytic anemiasulbactam

More Related Videos

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.1K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

4.9K

Related Experiment Videos

Last Updated: Oct 20, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.8K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.1K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

4.9K

Area of Science:

  • Pharmacology
  • Hematology
  • Internal Medicine

Background:

  • Drug-induced hemolytic anemia (DIHA) is a rare and often underdiagnosed adverse drug reaction.
  • Cefoperazone/sulbactam, a combination of a third-generation cephalosporin and a beta-lactamase inhibitor, is used for bacterial infections.
  • Limited data exist regarding DIHA specifically induced by cefoperazone/sulbactam.

Observation:

  • A 93-year-old female patient presented with an abdominal infection post-biliary tract surgery.
  • Hemolytic anemia developed within three days of initiating cefoperazone/sulbactam treatment.
  • Discontinuation of cefoperazone/sulbactam and substitution with meropenem led to the normalization of red blood cell parameters.

Findings:

  • The case report documents a probable instance of DIHA attributed to cefoperazone/sulbactam.
  • The patient's hematological parameters (red blood cells, hemoglobin, hematocrit) recovered after drug withdrawal.
  • This suggests a direct causal link between cefoperazone/sulbactam and the observed hemolytic anemia.

Implications:

  • Clinicians should maintain a high index of suspicion for DIHA when patients are treated with cefoperazone/sulbactam.
  • Vigilant monitoring for adverse reactions, particularly hematological changes, is crucial during cefoperazone/sulbactam therapy.
  • Prompt recognition and management of DIHA can prevent severe complications and ensure favorable patient outcomes.